Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease
JCI Insight · 2026
DOI: 10.1172/jci.insight.207552 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Viji Remadevi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jared Grantham Kidney Institute and. Hauptthemen laut MEDLINE: Pyridones, Polycystic Kidney, Autosomal Dominant, Kidney. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, American Heart Association.
Abstract (Originalsprache)
Autosomal dominant polycystic kidney disease (ADPKD) is a leading genetic cause of kidney failure, characterized by progressive cyst growth, inflammation, and interstitial fibrosis. Renal fibrosis, driven by myofibroblast activation and excessive extracellular matrix (ECM) deposition, is increasingly recognized as a key contributor to disease progression, yet targeted antifibrotic therapies remain limited. Here, we evaluated the therapeutic potential of pirfenidone to suppress fibrosis and disease progression in ADPKD. Single-nucleus RNA sequencing of human ADPKD kidneys identified fibroblasts as the predominant source of fibrous and adhesive ECM, with higher ECM-associated gene expression compared with that in normal kidney fibroblasts. In vitro, primary human ADPKD renal myofibroblasts displayed a similar profibrotic gene expression profile, and pirfenidone treatment suppressed ECM gene expression, cell proliferation, migration, and contractility. In the Pkd1 RC/RC mouse model of ADPKD, pirfenidone reduced renal fibrosis, myofibroblast accumulation, ECM deposition, profibrotic gene expression, and associated signaling pathways and improved kidney function. Pirfenidone also reduced kidney enlargement but reduced cyst burden only in female mice. Collectively, these findings demonstrate that pirfenidone attenuates renal fibrosis and improves kidney function in ADPKD by suppressing myofibroblast activation and ECM production, supporting fibrosis as a therapeutic target and highlighting pirfenidone as a potential adjunct to cyst-directed therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jared Grantham Kidney Institute and.
- Division of Nephrology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
- Research Service, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, USA.
- Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Cell Biology and Physiology Department, University of Kansas Medical Center, Kansas City, Kansas, USA.
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- American Heart Association
- United States Department of Veterans Affairs, Biomedical Laboratory Research and Development Service
Zitieren
APA
Remadevi, V., Jamadar, A., Varghese, M. M., Yang, H., Gunewardena, S., Wallace, D. P., & Rao, R. (2026). Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease. JCI Insight. https://doi.org/10.1172/jci.insight.207552
Vancouver
Remadevi V, Jamadar A, Varghese MM, Yang H, Gunewardena S, Wallace DP, et al. Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease. JCI Insight. 2026. doi:10.1172/jci.insight.207552
BibTeX
@article{Remadevi2026,
author = {Remadevi, Viji and Jamadar, Abeda and Varghese, Meekha M and Yang, Haichun and Gunewardena, Sumedha and Wallace, Darren P and Rao, Reena},
title = {Pirfenidone treatment attenuates fibrosis in autosomal dominant polycystic kidney disease},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.207552}
}
EUVIMED